• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

糖尿病性黄斑水肿患者抗血管内皮生长因子治疗中断后视力丧失的预测因素

Predictors of Vision Loss After Lapse in Antivascular Endothelial Growth Factor Treatment in Patients With Diabetic Macular Edema.

作者信息

Chalasani Meghana, Maatouk Christopher, Markle Jonathan, Singh Rishi P, Talcott Katherine E

机构信息

Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA.

Department of Ophthalmology, University of Chicago Medical Center, Chicago, IL, USA.

出版信息

J Vitreoretin Dis. 2024 Dec 13:24741264241305123. doi: 10.1177/24741264241305123.

DOI:10.1177/24741264241305123
PMID:39678936
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11645682/
Abstract

To identify baseline characteristics that predict visual outcomes after a lapse in treatment among patients with diabetic macular edema (DME) who received intravitreal antivascular endothelial growth factor injections. In this retrospective study, patients with DME who had lapses in treatment of 3 months or longer were separated into 2 groups (stable vision, n = 201; vision loss, n = 61) based on an Early Treatment Diabetic Retinopathy Study vision loss threshold of 10 letters. Stepwise backward logistic regression was used to analyze baseline factors associated with vision loss and to create a predictive algorithm. In the final regression model, the length of lapse in treatment (odds ratio [OR]; 1.15, 95% CI, 1.07-1.25), diabetic foot disease (OR, 3.02; 95% CI, 1.09-8.2), and Medicaid insurance (OR, 4.60; 95% CI, 1.20-18.7) were positively associated with vision loss ( .05). Time since diagnosis of diabetic retinopathy (OR, 0.95; 95% CI, 0.91-0.99) was negatively associated with vision loss ( .05). The final prediction model had a sensitivity of 20% and a specificity of 84%, with an area under the curve of 65%. For patients with DME at high risk for a lapse in treatment, baseline characteristics can help predict vision loss and guide management.

摘要

确定在接受玻璃体内抗血管内皮生长因子注射的糖尿病性黄斑水肿(DME)患者治疗中断后预测视力结果的基线特征。在这项回顾性研究中,治疗中断3个月或更长时间的DME患者根据早期糖尿病性视网膜病变研究中10个字母的视力丧失阈值被分为两组(视力稳定,n = 201;视力丧失,n = 61)。采用逐步向后逻辑回归分析与视力丧失相关的基线因素并创建预测算法。在最终回归模型中,治疗中断时长(比值比[OR];1.15,95%可信区间[CI],1.07 - 1.25)、糖尿病足病(OR,3.02;95% CI,1.09 - 8.2)和医疗补助保险(OR,4.60;95% CI,1.20 - 18.7)与视力丧失呈正相关(P < 0.05)。糖尿病性视网膜病变诊断后的时间(OR,0.95;95% CI,0.91 - 0.99)与视力丧失呈负相关(P < 0.05)。最终预测模型的敏感性为20%,特异性为84%,曲线下面积为65%。对于治疗中断风险高的DME患者,基线特征有助于预测视力丧失并指导管理。

相似文献

1
Predictors of Vision Loss After Lapse in Antivascular Endothelial Growth Factor Treatment in Patients With Diabetic Macular Edema.糖尿病性黄斑水肿患者抗血管内皮生长因子治疗中断后视力丧失的预测因素
J Vitreoretin Dis. 2024 Dec 13:24741264241305123. doi: 10.1177/24741264241305123.
2
Maintenance of Vision Needed to Drive after Intravitreal Anti-VEGF Therapy in Patients with Neovascular Age-related Macular Degeneration and Diabetic Macular Edema.新生血管性年龄相关性黄斑变性和糖尿病性黄斑水肿患者玻璃体内抗血管内皮生长因子治疗后需要保持视力以继续驾驶。
Ophthalmol Retina. 2024 Apr;8(4):388-398. doi: 10.1016/j.oret.2023.10.010. Epub 2023 Oct 20.
3
Effect of Intravitreous Anti-Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial.玻璃体腔内抗血管内皮生长因子与假治疗预防糖尿病视网膜病变致盲性并发症的效果:方案 W 随机临床试验。
JAMA Ophthalmol. 2021 Jul 1;139(7):701-712. doi: 10.1001/jamaophthalmol.2021.0606.
4
Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy.Protocol W 随机临床试验中玻璃体内注射阿柏西普预防糖尿病视网膜病变致盲性并发症的四年视觉结果。
JAMA. 2023 Feb 7;329(5):376-385. doi: 10.1001/jama.2022.25029.
5
The Short-term Effect of a Single Lapse in Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema Within Routine Clinical Practice.在常规临床实践中单次抗血管内皮生长因子治疗糖尿病黄斑水肿的短期效果。
Am J Ophthalmol. 2020 Nov;219:215-221. doi: 10.1016/j.ajo.2020.06.040. Epub 2020 Jul 5.
6
Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Factors Associated with Vision and Edema Outcomes.全视网膜光凝与雷珠单抗治疗增生型糖尿病视网膜病变:与视力和水肿结局相关的因素。
Ophthalmology. 2018 Nov;125(11):1776-1783. doi: 10.1016/j.ophtha.2018.04.039. Epub 2018 Jul 3.
7
Standard threshold laser versus subthreshold micropulse laser for adults with diabetic macular oedema: the DIAMONDS non-inferiority RCT.标准阈值激光与亚阈值微脉冲激光治疗成人糖尿病性黄斑水肿:DIAMONDS 非劣效性 RCT。
Health Technol Assess. 2022 Dec;26(50):1-86. doi: 10.3310/SZKI2484.
8
Characterization of Poor Visual Outcomes of Diabetic Macular Edema: The Fight Retinal Blindness! Project.糖尿病性黄斑水肿不良视觉结局的特征:抗击视网膜病变!计划。
Ophthalmol Retina. 2022 Jul;6(7):540-547. doi: 10.1016/j.oret.2022.03.007. Epub 2022 Mar 17.
9
Microinvasive pars plana vitrectomy combined with internal limiting membrane peeling versus anti-VEGF intravitreal injection for treatment-naïve diabetic macular edema (VVV-DME study): study protocol for a randomized controlled trial.微创新庄玻璃体切除术联合内界膜剥除与抗 VEGF 玻璃体注射治疗初治糖尿病黄斑水肿(VVV-DME 研究):一项随机对照试验的研究方案。
Trials. 2023 Oct 24;24(1):685. doi: 10.1186/s13063-023-07735-w.
10
Predictors of response to a lapse in anti-VEGF treatment in patients with macular edema secondary to retinal vein occlusion.预测视网膜静脉阻塞继发黄斑水肿患者抗 VEGF 治疗中断后反应的因素。
Can J Ophthalmol. 2024 Oct;59(5):e568-e574. doi: 10.1016/j.jcjo.2023.08.002. Epub 2023 Sep 14.

引用本文的文献

1
Issues in Medicine: Equity and Site Neutrality.医学问题:公平性与场地中立性
J Vitreoretin Dis. 2025 Mar 16;9(2):125-130. doi: 10.1177/24741264251322832. eCollection 2025 Mar-Apr.

本文引用的文献

1
Sociodemographic variables associated with risk for diabetic retinopathy.与糖尿病视网膜病变风险相关的社会人口统计学变量。
Clin Diabetes Endocrinol. 2022 Oct 24;8(1):7. doi: 10.1186/s40842-022-00144-z.
2
Impact of the COVID-19 pandemic on visual outcomes of diabetic macular edema patients at a tertiary care veterans affairs center.2019年冠状病毒病大流行对一家三级医疗退伍军人事务中心糖尿病性黄斑水肿患者视力预后的影响。
J Diabetes Metab Disord. 2022 May 12;21(1):759-768. doi: 10.1007/s40200-022-01049-5. eCollection 2022 Jun.
3
Prevalence of diabetic macular edema based on optical coherence tomography in people with diabetes: A systematic review and meta-analysis.基于光学相干断层扫描的糖尿病患者糖尿病性黄斑水肿患病率:系统评价和荟萃分析。
Surv Ophthalmol. 2022 Jul-Aug;67(4):1244-1251. doi: 10.1016/j.survophthal.2022.01.009. Epub 2022 Jan 31.
4
Conversion of Central Subfield Thickness Measurements of Diabetic Macular Edema Across Cirrus and Spectralis Optical Coherence Tomography Instruments.糖尿病性黄斑水肿的中央凹视网膜厚度测量值在 Cirrus 和 Spectralis 光学相干断层扫描仪之间的转换。
Transl Vis Sci Technol. 2021 Dec 1;10(14):34. doi: 10.1167/tvst.10.14.34.
5
Optical Coherence Tomography Classification Systems for Diabetic Macular Edema and Their Associations With Visual Outcome and Treatment Responses - An Updated Review.光学相干断层扫描分类系统在糖尿病性黄斑水肿及其与视觉结局和治疗反应的相关性中的应用——最新综述。
Asia Pac J Ophthalmol (Phila). 2022 Jun 1;11(3):247-257. doi: 10.1097/APO.0000000000000468.
6
Race and Socioeconomic Status in Anti-VEGF Treatment of Diabetic Macular Edema.种族和社会经济地位与糖尿病性黄斑水肿抗 VEGF 治疗。
Ophthalmic Surg Lasers Imaging Retina. 2021 Nov;52(11):578-585. doi: 10.3928/23258160-20211018-01. Epub 2021 Nov 1.
7
Lapses in Care Among Patients Assigned to Ranibizumab for Proliferative Diabetic Retinopathy: A Post Hoc Analysis of a Randomized Clinical Trial.接受雷珠单抗治疗增生性糖尿病视网膜病变患者的护理失误:一项随机临床试验的事后分析。
JAMA Ophthalmol. 2021 Dec 1;139(12):1266-1273. doi: 10.1001/jamaophthalmol.2021.4103.
8
Social determinants of health impacting adherence to diabetic retinopathy examinations.影响糖尿病视网膜病变检查依从性的健康社会决定因素。
BMJ Open Diabetes Res Care. 2021 Sep;9(1). doi: 10.1136/bmjdrc-2021-002374.
9
Outcomes of Eyes With Diabetic Macular Edema That Are Lost to Follow-up After Anti-Vascular Endothelial Growth Factor Therapy.抗血管内皮生长因子治疗后失访的糖尿病性黄斑水肿眼的结局
Am J Ophthalmol. 2022 Jan;233:1-7. doi: 10.1016/j.ajo.2021.06.028. Epub 2021 Jul 17.
10
The Short-term Effect of a Single Lapse in Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema Within Routine Clinical Practice.在常规临床实践中单次抗血管内皮生长因子治疗糖尿病黄斑水肿的短期效果。
Am J Ophthalmol. 2020 Nov;219:215-221. doi: 10.1016/j.ajo.2020.06.040. Epub 2020 Jul 5.